Lanthane Viatris

Lanthanum, the active ingredient in Lanthane Viatris, is a phosphate binder presented as an oral formulation for oral use. It binds dietary phosphate in the gastrointestinal tract, forming insoluble complexes that are excreted, and is employed to treat hyperphosphatemia in patients with chronic kidney disease, particularly those on dialysis.

GNH USA supplies Lanthane Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, with distribution originating from the European Union market.

Lanthane Viatris is a phosphate binder used to manage elevated serum phosphate levels in chronic kidney disease.

Hyperphosphatemia in chronic kidney disease: lowers serum phosphate concentrations. Patients on dialysis: helps maintain phosphate balance and reduces the need for strict dietary restrictions. End‑stage renal disease: contributes to lowering the risk of vascular calcification associated with high phosphate.

Lanthane Viatris may cause gastrointestinal and metabolic adverse reactions.

Common Side Effects: - Nausea - Constipation - Abdominal discomfort - Metallic taste

Serious or Rare Side Effects: - Severe constipation leading to bowel obstruction - Hypophosphatemia (excessively low serum phosphate) - Gastrointestinal ulceration or bleeding

Before initiating therapy, consider the following precautions.

Monitor serum phosphate: check levels regularly to adjust therapy. Assess calcium balance: avoid concurrent high calcium intake that may cause hypercalcemia. Evaluate gastrointestinal health: patients with existing bowel disorders may have increased risk of obstruction. Review concomitant phosphate binders: avoid using multiple binders simultaneously without medical supervision. Store below 25°C: keep in the original container, protect from moisture and direct sunlight.

Lanthane Viatris can interact with several medicines; awareness helps maintain efficacy and safety.

Major Interactions (Avoid): - Iron supplements (e.g., ferrous sulfate): reduce lanthanum binding efficacy. - Calcium carbonate or calcium acetate: compete for phosphate binding sites. - Sevelamer: additive phosphate binding may cause excessive phosphate depletion.

Moderate Interactions (Monitor Closely): - Vitamin D analogs (e.g., calcitriol): may increase calcium absorption, requiring monitoring. - Proton pump inhibitors: may alter gastric pH and affect lanthanum solubility.